Teva Chosen As 'Bellwether' In US Price-Fixing Litigation
Case Involving Israeli Generics Giant Selected As Priority For Trial
Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.
You may also be interested in...
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
Glenmark has issued a forceful rebuttal over US price-fixing charges being pursued by the country’s Department of Justice covering drugs such as pravastatin.
A third major price-fixing lawsuit has been filed in the US, naming over two dozen companies and ten individuals in allegations covering 80 generic presentations, focusing in particular on topical drugs.